Infectious Complications in Patients with Relapsed or Refractory (R/R) Non-Hodgkin's Lymphoma (NHL) Treated with the Anti-CD20xCD3 Bispecific Antibody (BsAb) Mosunetuzumab

被引：2

作者：

Shahid, Zainab ^{[1
,2
]}

Okwali, Michelle ^{[3
]}

Joseph, Ashlee ^{[4
]}

Seo, Susan K. ^{[2
,5
]}

Lue, Jennifer Kimberly ^{[4
]}

Boardman, Alexander P. ^{[3
]}

Caron, Philip ^{[3
]}

David, Kevin A. ^{[3
]}

Epstein-Peterson, Zachary D. ^{[3
]}

Ghione, Paola ^{[4
]}

Hamlin, Paul A. ^{[3
]}

Horwitz, Steven M. ^{[4
]}

Intlekofer, Andrew M. ^{[3
]}

Johnson, William ^{[4
]}

Kumar, Anita ^{[6
]}

Moskowitz, Alison ^{[4
]}

Noy, Ariela ^{[3
]}

Owens, Colette ^{[3
]}

Palomba, Maria Lia ^{[3
]}

Stuver, Robert ^{[4
]}

Torka, Pallawi ^{[3
]}

Vardhana, Santosha A. ^{[3
]}

Zelenetz, Andrew D. ^{[3
]}

Salles, Gilles ^{[3
]}

Falchi, Lorenzo ^{[3
]}

机构：

[1] Mem Sloan Kettering Canc Ctr, Infect Dis Serv, New York, NY USA

[2] Weill Cornell Med, Dept Med, New York, NY USA

[3] Mem Sloan Kettering Canc Ctr, Dept Med, Lymphoma Serv, New York, NY USA

[4] Mem Sloan Kettering Canc Ctr, New York, NY USA

[5] Mem Sloan Kettering Canc Ctr, Dept Med, Infect Dis Serv, New York, NY USA

[6] Mem Sloan Kettering Canc Ctr, Dept Med, Lymphoma Serv, Short Hills, NJ USA

来源：

BLOOD | 2023年 / 142卷

关键词：

D O I：

10.1182/blood-2023-187911

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

引用

页数：5

共 50 条

[1] Population Pharmacokinetics and CD20 Binding Dynamics for Mosunetuzumab in Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma (R/R NHL)
Bender, Brendan C.
Li, Chi-Chung
Marchand, Mathilde
Turner, David C.
Li, Feifei
Vadhavkar, Shweta
Wang, Bei
Deng, Rong
Lu, James
Jin, Jin
Li, Chunze
Yin, Shen
Wei, Michael C.
Chanu, Pascal
BLOOD, 2023, 142
[2] Pharmacodynamic Effects and Immune Correlates of Response to the CD20/CD3 Bispecific Antibody Mosunetuzumab in Relapsed or Refractory Non-Hodgkin Lymphoma
Hernandez, Genevive
Huw, Ling-Yuh
Belousov, Anton
Wilson, Deanna
Koeppen, Hartmut
McCord, Ron
Peng, Kun
Bartlett, Nancy L.
Budde, Lihua E.
Assouline, Sarit
Nastoupil, Loretta J.
Yoon, Dok Hyun
Matasar, Matthew J.
Bender, Brendan
Kwan, Antonia
Li, Chi-Chung
O'Hear, Carol
Yin, Shen
Wei, Michael C.
Adamkewicz, Joanne I.
BLOOD, 2019, 134
[3] Clinical Activity of REGN1979, a Bispecific Human, Anti-CD20 x Anti-CD3 Antibody, in Patients with Relapsed/Refractory (R/R) B-Cell Non-Hodgkin Lymphoma (B-NHL)
Bannerji, Rajat
Allan, John N.
Arnason, Jon E.
Brown, Jennifer R.
Advani, Ranjana H.
Barnes, Jeffrey A.
Ansell, Stephen M.
O'Brien, Susan M.
Chavez, Julio
Duell, Johannes
David, Kevin A.
Martin, Peter
Joyce, Robin M.
Charnas, Robert
Ambati, Srikanth R.
Adriaens, Lieve
Ufkin, Melanie
Zhu, Min
Li, Jingjin
Gasparini, Peter
Ibrahim, Anfal
Jankovic, Vladimir
Fiaschi, Nathalie
Aina, Olulanu
Zhang, Wen
Deering, Raquel P.
Hamon, Sara
Thurston, Gavin
Murphy, Andrew J.
Weinreich, David M.
Yancopoulos, George D.
Lowy, Israel
Sternberg, David
Topp, Max S.
BLOOD, 2019, 134
[4] Anti-CD47 Antibody, CC-90002, in Combination with Rituximab in Subjects with Relapsed and/or Refractory Non-Hodgkin Lymphoma (R/R NHL)
Abrisqueta, Pau
Sancho, Juan-Manuel
Cordoba, Raul
Persky, Daniel O.
Andreadis, Charalambos
Huntington, Scott F.
Carpio, Cecilia
Giles, Daniel Morillo
Wei, Xin
Li, Ying Fei
Zuraek, Marlene
Burgess, Michael R.
Hege, Kristen
Martin, Alejandro
BLOOD, 2019, 134
[5] A Phase 2 Study of REGN1979, an Anti-CD20 x Anti-CD3 Bispecific Antibody (Ab), in Patients with Relapsed/Refractory (R/R) B-Cell Non-Hodgkin Lymphoma (B-NHL)
Topp, Max S.
Duell, Johannes
Li, Jingjin
Jankovic, Vladimir
Lowy, Israel
Sternberg, David
Adriaens, Lieve
Peterman, Mary
Ambati, Srikanth R.
Bannerji, Rajat
BLOOD, 2019, 134
[6] Managing cytokine release syndrome (CRS) and neurotoxicity with step-fractionated dosing of mosunetuzumab in relapsed/refractory (R/R) B-cell non-Hodgkin lymphoma (NHL).
Bartlett, Nancy L.
Sehn, Laurie Helen
Assouline, Sarit E.
Bosch, Francesc
Diefenbach, Catherine S. Magid
Flinn, Ian
Hong, Jungyong
Kim, Wonseog S.
Matasar, Matthew J.
Nastoupil, Loretta J.
Schuster, Stephen J.
Shadman, Mazyar
Yoon, Sung-Soo
Bender, Brendan
Kwan, Antonia
Wang Cunlin
Wei, Michael C.
Yin, Shen
Yousefi, Kasra
Budde, L. Elizabeth
JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
[7] Preparing Nurses for CD20-CD3 Bispecific Antibody Treatment in Patients With Non-Hodgkin Lymphoma
van der Linde, Sam
Knights, Emily
Robertson, Molly
Krishnasamy, Meinir
Minson, Adrian
Dickinson, Michael
CANCER NURSING, 2024,
[8] Phase I study of CN201, a novel CD3xCD19 bispecific antibody, in patients with relapsed or refractory B-cell non-Hodgkin lymphoma
Xie, Yang
Cai, Qingqing
Liu, Haisheng
Guo, Ye
Huang, Wenrong
Zhang, Mingzhi
Xia, Yi
Gao, Yuhuan
Chen, Xilin
Tang, Yongjing
Yin, Shaoning
Yuan, Shunzong
Li, Haiying
Song, Yuqin
JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
[9] Molecular assessment of intratumoral immune cell subsets and potential mechanisms of resistance to odronextamab, a CD20xCD3 bispecific antibody, in patients with relapsed/refractory B-cell non-Hodgkin lymphoma
Brouwer-Visser, Jurriaan
Fiaschi, Nathalie
Deering, Raquel P.
Cygan, Kamil J.
Scott, Darius
Jeong, Se
Boucher, Lauren
Gupta, Namita T.
Gupta, Suraj
Adler, Christina
Topp, Max S.
Bannerji, Rajat
Duell, Johannes
Advani, Ranjana H.
Flink, Dina M.
Chaudhry, Aafia
Thurston, Gavin
Ambati, Srikanth R.
Jankovic, Vladimir
JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2024, 12 (03)
[10] Safety and Anti-Tumor Activity of Plamotamab (XmAb13676), an Anti-CD20 x Anti-CD3 Bispecific Antibody, in Subjects with Relapsed/Refractory Non-Hodgkin's Lymphoma
Patel, Krish
Michot, Jean-Marie
Chanan-Khan, Asher
Ghesquieres, Herve
Bouabdallah, Kamal
Byrd, John C.
Cartron, Guillaume
Portell, Craig A.
Solh, Melhem
Tilly, Herve
Wierda, William G.
McGovern, Patricia
Johnson, Chelsea
Garcha, Raman
Ribrag, Vincent
Brisou, Gabriel
Liebowitz, David
Phillips, Tycel
BLOOD, 2021, 138

← 1 2 3 4 5 →